Semi-annual Performance Forecast for 2026
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
The company expects to achieve a net profit attributable to shareholders within a specified range, which reflects a substantial decrease from the prior period. The forecast highlights that the anticipated decrease in profit is primarily due to changes in product sales structure and increased financial expenses. Investors are cautioned that these figures are preliminary and have not been audited, with final results to be disclosed in the official report.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/zhejiang-huakang-pharmaceutical-co-ltdsemi-annual-performance-forecast-for-2026
Zhejiang Huakang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huakang Pharmaceutical
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Addition of Implementing Entities for Projects Funded by the Convertible Corporate Bond Issued to Non-specific Objects
- Announcement on Adjusting the Total Cash Dividends for the 2025 Annual Profit Distribution
- Announcement on Abnormal Fluctuations in Stock Trading
- Indicative Announcement on Stopping Conversion of "Huakang Convertible Bonds" when Implementing 2025 Annual Dividend Distribution
Later from Zhejiang Huakang Pharmaceutical
- Announcement on Not Revising Downward the Conversion Price of "Huakang Convertible Bonds"
- Announcement on the Implementation of the Repurchase and Cancellation of Certain Restricted Shares under the Equity Incentive Plan
- Announcement on Resolutions of the 4th Meeting of the 7th Board of Directors
- Announcement on Completion of Repurchase and Cancellation of Certain Restricted Shares and Adjustment to the Conversion Price of "Huakang Convertible Bonds"
- Announcement on Progress in Providing Guarantee Limit for Wholly-owned Subsidiary
Follow Zhejiang Huakang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huakang Pharmaceutical